Otwarty dostęp

Emicizumab in two patients with acquired haemophilia A – case report

Milly Zhao

Milly Zhao

Department of Pharmacy, New York-Presbyterian/Weill Cornell Medical CenterNew York, USA
Wyszukaj tego autora
Sciendo|Google Scholar
Zhao, Milly
, 
Thomas Kartika

Thomas Kartika

Division of Hematology and Medical Oncology, Department of Medicine, New York-Presbyterian/Weill Cornell Medical CenterNew York, USA
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
Kartika, Thomas
, 
Corey Witenko

Corey Witenko

Department of Pharmacy, New York-Presbyterian/Weill Cornell Medical CenterNew York, USA
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
Witenko, Corey
, 
Jessica Snead

Jessica Snead

Department of Pharmacy, New York University Langone HealthBrooklyn, USA
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
Snead, Jessica
, 
Maria T DeSancho

Maria T DeSancho

Division of Hematology and Medical Oncology, Department of Medicine, New York-Presbyterian/Weill Cornell Medical CenterNew York, USA
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
DeSancho, Maria T
 oraz 
Alana Ciolek

Alana Ciolek

Department of Pharmacy, New York-Presbyterian/Weill Cornell Medical CenterNew York, USA
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
Ciolek, Alana
  
02 sie 2024
Emicizumab in two patients with acquired haemophilia A – case report's Cover Image
O artykule
Poprzedni artykuł
Następny artykuł
Zacytuj
Pobierz okładkę
Kategoria artykułu: Case Study
Data publikacji: 02 sie 2024
Zakres stron: 92 - 98
DOI: https://doi.org/10.2478/jhp-2024-0016
Słowa kluczowe
© 2024 Milly Zhao et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The cases of two patients with acquired haemophilia A treated with emicizumab suggest its early initiation as part of frontline therapy may reduce episodes of bleeding and reduce the need for bypassing agents
The cases of two patients with acquired haemophilia A treated with emicizumab suggest its early initiation as part of frontline therapy may reduce episodes of bleeding and reduce the need for bypassing agents

Figure 1.

Timeline of events in care of the first patient Days are with respect to the initial presentation. The patient’s coagulation parameters and FVIII levels and inhibitor are shown in relation to administration of haemostatic agents and immunosuppressive therapy (IST) including rituximab and prednisone. On day 67 and 74, the Factor VIII levels on the one-stage assay (FVIII:h) were 273 and 278%, respectively [not shown]. Patient had debridement done on day 70 and initiated on recombinant factor VIIa (rFVIIa), subsequently developing a deep vein thrombus on day 76. aPTT = activated partial thromboplastin time; FVIII:b = chromogenic FVIII measurement using bovine reagent; aPCC = activated prothrombin complex concentrate; LMWH = low molecular weight heparin
Timeline of events in care of the first patient Days are with respect to the initial presentation. The patient’s coagulation parameters and FVIII levels and inhibitor are shown in relation to administration of haemostatic agents and immunosuppressive therapy (IST) including rituximab and prednisone. On day 67 and 74, the Factor VIII levels on the one-stage assay (FVIII:h) were 273 and 278%, respectively [not shown]. Patient had debridement done on day 70 and initiated on recombinant factor VIIa (rFVIIa), subsequently developing a deep vein thrombus on day 76. aPTT = activated partial thromboplastin time; FVIII:b = chromogenic FVIII measurement using bovine reagent; aPCC = activated prothrombin complex concentrate; LMWH = low molecular weight heparin

Figure 2.

Timeline of events in care of the second patient Days are with respect to the initial presentation. The patient’s coagulation parameters and Factor VIII (FVIII) levels and inhibitor are shown in relation to administration of haemostatic agents and immunosuppressive therapy (IST) including intravenous immunoglobulin, prednisone, rituximab, and cyclophosphamide. During recurrence, the patient received 3 doses of emicizumab. Inhibitor level became undetectable three months post relapse. aPTT = activated partial thromboplastin time; FVIII:h = FVIII measurement via one-stage assay; FVIII:b = chromogenic FVIII measurement using bovine reagent; aPCC = activated prothrombin complex concentrate
Timeline of events in care of the second patient Days are with respect to the initial presentation. The patient’s coagulation parameters and Factor VIII (FVIII) levels and inhibitor are shown in relation to administration of haemostatic agents and immunosuppressive therapy (IST) including intravenous immunoglobulin, prednisone, rituximab, and cyclophosphamide. During recurrence, the patient received 3 doses of emicizumab. Inhibitor level became undetectable three months post relapse. aPTT = activated partial thromboplastin time; FVIII:h = FVIII measurement via one-stage assay; FVIII:b = chromogenic FVIII measurement using bovine reagent; aPCC = activated prothrombin complex concentrate
Język:
Angielski
Częstotliwość wydawania:
1 razy w roku
Dziedziny czasopisma:
Medycyna, Podstawowe nauki medyczne, Podstawowe nauki medyczne, inne, Medycyna kliniczna, Medycyna kliniczna, inne, Farmacja, Farmakologia
Kanał RSS czasopisma